FDA perspectives on postmarket surveillance of peripheral and aortic vascular devices

Case examples in Pyun et al., highlight value of RWD to elucidate real-world outcomes in expanded patient population and to discern potential signals. CDRH actively engages with stakeholders through transparent communication and collaboration to resolve signals. Additional improvements in the RWD infrastructure are warranted to ensure complete and accurate data collection across the total product lifecycle.